Login to Your Account

Praecis Still Expects Plenaxis Approval Despite 3-Month Delay

By Aaron Lorenzo

Tuesday, July 22, 2003
Praecis Pharmaceuticals Inc. continues to expect regulatory approval for Plenaxis despite an FDA decision to delay action on the new drug application by three months. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription